REVEAL: A Phase 3 Study of Obudanersen (ION582) in Angelman Syndrome (NCT06914609)
Phase 3 Study of the Efficacy and Safety of ION582 in Children and Adults With Angelman Syndrome
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to evaluate the efficacy and safety of obudanersen in children and adults with Angelman syndrome caused by a deletion or mutation of the UBE3A gene.
Who can join: Review the eligibility criteria below.
Location: Cedars-Sinai Medical Center — Los Angeles, California
Age range: 2 Years to 50 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (41 Sites)
Showing the first 25 of 41 sites.
- Cedars-Sinai Medical Center — Los Angeles, California
- UCLA Clinical & Translational Research Center (CTRC) — Los Angeles, California
- Rady Children's Hospital — San Diego, California
- Colorado Children's Hospital Research Institute — Aurora, Colorado
- Children's National Hospital — Washington D.C., District of Columbia
- Nicklaus Children's Hospital — Miami, Florida
- Children's Healthcare of Atlanta — Atlanta, Georgia
- Rush University Medical Center — Chicago, Illinois
- Boston Children's Hospital — Boston, Massachusetts
- Children's Mercy — Kansas City, Missouri
- Ichan School of Medicine at Mount Sinai — New York, New York
- Columbia University Irving Medical Center — New York, New York
- University of North Carolina at Chapel Hill School of Medicine — Carrboro, North Carolina
- Cincinnati Children's Hospital — Cincinnati, Ohio
- Nationwide Children's Hospital — Columbus, Ohio
- Children's Hospital of Philadelphia — Philadelphia, Pennsylvania
- Vanderbilt Clinical Research Center — Nashville, Tennessee
- Texas Children's Hospital — Houston, Texas
- Queensland Children's Hospital — South Brisbane, Queensland
- Austin Hospital — Heidelberg,
- Perth Children's Hospital — Nedlands,
- Sydney Children's Hospital — Randwick,
- London Health Science Centre - Children's Hospital — London, Ontario
- McGill University Health Centre — Montreal, Quebec
- University of Alberta Hospital — Edmonton,
📞 Contact the Study Coordinator
Phone: (844) 285-7172
Email: IonisION582-CS2@clinicaltrialmedia.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Angelman Syndrome
- HALOS: A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Multiple Ascending Doses of ION582 in Participants With Angelman Syndrome — San Diego, California
- Phase 3 Efficacy and Safety Study of GTX-102 in Pediatric Subjects With Angelman Syndrome (AS) — Los Angeles, California
- Angelman Syndrome Natural History Study — Los Angeles, California
- A Phase 1/2 Study of the Safety and Efficacy of MVX-220 in Angelman Syndrome — Los Angeles, California
- BEACON - Phase III Clinical Study of Rugonersen in Angelman Syndrome. — San Diego, California
- A Natural History Study of Angelman Syndrome — Lexington, Massachusetts
Explore by condition: All Angelman Syndrome clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.